Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Sverre Christian Christiansen"'
Autor:
Ingrid Anna Teigen, M.D., Ph.D., Marte Kierulf Åm, Ph.D., Misbah Riaz, M.D., Sverre Christian Christiansen, M.D., Ph.D., Sven Magnus Carlsen, M.D., Ph.D.
Publikováno v:
Current Therapeutic Research, Vol 100, Iss , Pp 100736- (2024)
ABSTRACT: Background: Slow insulin absorption prevents the development of a fully automated artificial pancreas with subcutaneous insulin delivery. Objective: We have hypothesized that glucagon could be used as a vasodilator to accelerate insulin abs
Externí odkaz:
https://doaj.org/article/2c399124ae2d4713a7185a0d69b37b95
Autor:
Ingrid Anna Teigen, Misbah Riaz, Marte Kierulf Åm, Sverre Christian Christiansen, Sven Magnus Carlsen
Publikováno v:
Frontiers in Bioengineering and Biotechnology, Vol 10 (2022)
Patients with diabetes mellitus type 1 depend on exogenous insulin to keep their blood glucose concentrations within the desired range. Subcutaneous bihormonal artificial pancreas devices that can measure glucose concentrations continuously and auton
Externí odkaz:
https://doaj.org/article/dbc20b7eb10147f79eb9fa06440f745d
Autor:
Sven Magnus Carlsen, Ilze Dirnena-Fusini, Marte Kierulf Åm, Anders Lyngvi Fougner, Sverre Christian Christiansen
Publikováno v:
BMJ Open Diabetes Research & Care, Vol 9, Iss 1 (2021)
Introduction The effect of intraperitoneal insulin infusion has limited evidence in the literature. Therefore, the aim of the study was to investigate the pharmacokinetics and pharmacodynamics of different intraperitoneal insulin boluses. There is a
Externí odkaz:
https://doaj.org/article/53f5c09390a348d1b1976da4956ad33a
Autor:
Ilze Dirnena-Fusini, Marte Kierulf Åm, Anders Lyngvi Fougner, Sven Magnus Carlsen, Sverre Christian Christiansen
Publikováno v:
PLoS ONE, Vol 16, Iss 4, p e0249611 (2021)
The intraperitoneal route of administration accounts for less than 1% of insulin treatment regimes in patients with diabetes mellitus type 1 (DM1). Despite being used for decades, a systematic review of various physiological effects of this route of
Externí odkaz:
https://doaj.org/article/468ccdfe396040018dbf4e4f77656a91
Autor:
Marte Kierulf Åm, Konstanze Kölle, Anders Lyngvi Fougner, Ilze Dirnena-Fusini, Patrick Christian Bösch, Reinold Ellingsen, Dag Roar Hjelme, Øyvind Stavdahl, Sven Magnus Carlsen, Sverre Christian Christiansen
Publikováno v:
PLoS ONE, Vol 13, Iss 10, p e0205447 (2018)
BACKGROUND:In diabetes research, the development of the artificial pancreas has been a major topic since continuous glucose monitoring became available in the early 2000's. A prerequisite for an artificial pancreas is fast and reliable glucose sensin
Externí odkaz:
https://doaj.org/article/cb243709b31f48b894be4a8254627eb3
Autor:
Odd Martin Staal, Heidi Marie Umbach Hansen, Sverre Christian Christiansen, Anders Lyngvi Fougner, Sven Magnus Carlsen, Øyvind Stavdahl
Publikováno v:
Biosensors, Vol 8, Iss 4, p 93 (2018)
Freestyle Libre (FL) is a factory calibrated Flash Glucose Monitor (FGM). We investigated Mean Absolute Relative Difference (MARD) between Self Monitoring of Blood Glucose (SMBG) and FL measurements in the first day of sensor wear in 39 subjects with
Externí odkaz:
https://doaj.org/article/800f911575314c36afa168cdda8c1576
Publikováno v:
European journal of drug metabolism and pharmacokinetics
European Journal of Drug Metabolism and Pharmacokinetics
European Journal of Drug Metabolism and Pharmacokinetics
Background and Objective Artificial pancreases administering low-dose glucagon in addition to insulin have the scope to improve glucose control in patients with diabetes mellitus type 1. If such a device were to deliver both hormones intraperitoneall
Publikováno v:
Basicclinical pharmacologytoxicology. 130(6)
There is increasing scientific evidence to substantiate using low-dose glucagon as a supplement to insulin therapy in artificial pancreata for diabetes mellitus type 1. The delivery of both these hormones intraperitoneally would mimic normal physiolo
Autor:
Marte Kierulf Åm, Erlend Yttersian Munkerud, Mathilde Hallem Berge, Sverre Christian Christiansen, Sven Magnus Carlsen
Publikováno v:
European Journal of Pharmacology
Introduction Glucagon and insulin are the two most important hormones for glucose metabolism and have been incorporated in the dual-hormonal artificial pancreas, a device for automated glucose regulation for people with diabetes type 1. Currently the
Autor:
Anders Lyngvi Fougner, Sverre Christian Christiansen, Marte Kierulf Åm, Sven M. Carlsen, Ilze Dirnena-Fusini
Publikováno v:
Scientific Reports
Scientific Reports, Vol 10, Iss 1, Pp 1-8 (2020)
Scientific Reports, Vol 10, Iss 1, Pp 1-8 (2020)
Glucagon is a pancreatic hormone and increases the blood glucose levels. It may be incorporated in a dual hormone artificial pancreas, a device to automatically and continuously control blood glucose levels of individuals with diabetes. Artificial pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7bcec83bfe5431dbaac511df7bc47ee
https://hdl.handle.net/11250/2679723
https://hdl.handle.net/11250/2679723